⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6912539 | 0.92 | CA4 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL4342494 | 0.92 | CA4 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL20569310 | 0.92 | — | — | |
| Trifluoroacetic Acid SCHEMBL108536 | 0.92 | — | — | |
| Trifluoroacetic Acid SCHEMBL204190 | 0.92 | CA4 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL4398806 | 0.92 | — | — | |
| Trifluoroacetic Acid SCHEMBL20541013 | 0.92 | CA4 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL20571141 | 0.92 | CA4 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL20569660 | 0.92 | CA4 (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL2381055 | 0.92 | CA4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| CN-103988127-B | Photosensitive resin composition, method for producing cured relief pattern, semiconductor device, and display device | 旭化成株式会社 | 2019-04-19 | — | — | CN | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| CN-107329367-A | Photosensitive resin composition, method for producing cured relief pattern, semiconductor device, and display device | 旭化成株式会社 | 2017-11-07 | — | — | CN | disclosed |
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| CN-102439520-A | Photosensitive resin composition | ASAHI KASEI E MATERIALS CORP | 2012-05-02 | — | — | CN | disclosed |
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128058-A2 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1689383-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| CN-1137378-A | Use of HCPSH2 specific compounds to enhance erythropoiesis | SMITHKLINE BEECHAM CORP (US) | 1996-12-11 | — | — | CN | disclosed |
| CN-1135333-A | Usage of SRCSH2 specific compound for treatment of bone absorption disease | SMITHKLINE BEECHAM CORP (US) | 1996-11-13 | — | — | CN | disclosed |